Patients with sarcoma of the extremity who have a good performance status may easily tolerate a protracted course of adjuvant RT following LSS, even if induction chemotherapy or tumor-necrosis factor via isolated limb perfusion had been primarily administered [2]. This evidence concerns the gene TNF and sarcoma.